Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Not a discussion board

"the uncertainty of the Markman ruling operates as a disincentive to large accumulation of shares by any one person or small group."

Yes it does. Anyone doing all this accumulation would have to be privy to info most of us are not.That is why I believe that the accumulation is being done by licensees. They have been in negoiations for months, if not years years. They know all the details of the patents, and surely know that they have been infringeing for years. The outcome of the trial may be almost certain to them.

They made the smart move of buying at a discount, which by the way is a drop in the bucket to them.Why not spend a little more to break even or possibly turn a nice profit.

What baffled me are the ones that are left, the J2.Why did they not settle? Perhaps it is not their choice. Somebody always has to pay dearly.

 

Share
New Message
Please login to post a reply